Pre-clinical studies of a new quinolone (UB-8902) against Acinetobacter baumannii resistant to ciprofloxacin

International Journal of Antimicrobial Agents

Volumn 38, Issue 4, 2011, Pages 355-359

  Lopez Rojas R ^a,b   Sanchez Cespedes J ^b,c   Docobo Perez F ^a,b   Dominguez Herrera J ^a,b   Vila, J ^b,c   Pachon J ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b ISCIII RD06/0008   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Acinetobacter baumannii; Ciprofloxacin resistance; Experimental pneumonia; Pharmacokinetics pharmacodynamics; Quinolones; UB 8902

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; MOXIFLOXACIN; UB 8902; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BLOOD CULTURE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LD 50; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PNEUMONIA; PREDICTION; PRIORITY JOURNAL;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; ANTI-INFECTIVE AGENTS; BLOOD BACTERICIDAL ACTIVITY; CIPROFLOXACIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; FLUOROQUINOLONES; LETHAL DOSE 50; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; MOLECULAR CONFORMATION; PNEUMONIA; QUINOLONES;

EID: 80052273750     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2011.06.006     Document Type: Article

References (15)

1. L.S. Munoz-Price, and R.A. Weinstein Acinetobacter infection N Engl J Med 358 2008 1271 1281
2. J. Vila, J. Ruiz, P. Goñi, and T. Jimenez de Anta Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii J Antimicrob Chemother 39 1997 757 762 (Pubitemid 27296416)
3. J. Vila, J. Sánchez-Céspedes, J.M. Sierra, M. Piqueras, E. Nicolas, and J. Freixas Antibacterial evaluation of a collection of norfloxacin and ciprofloxacin derivatives against multiresistant bacteria Int J Antimicrob Agents 28 2006 19 24
4. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 17th informational supplement. Document M100-S17. Wayne, PA: CLSI; 2007.
5. National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents; approved standard. Document M26-A. Wayne, PA: NCCLS; 1999.
6. T. O'Reilly, R. Cleeland, and E.L. Squires Evaluation of antimicrobials in experimental animal infections V. Lorian, Antibiotics in laboratory medicine 4th ed. 1996 Lippincott Williams and Wilkins Baltimore, MD 604 765
7. J.L. Usansky, A. Desai, and D. Tang-Liu PK functions for Microsoft Excel 2010 Department of Pharmacokinetics and Drug Metabolism, Allergan Irvine, CA http://www.boomer.org/pkin/soft.html [accessed 24 February 2011]
8. M.J. Rodríguez-Hernández, J. Pachón, C. Pichardo, L. Cuberos, J. Ibáñez-Martínez, and A. García-Curiel Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia J Antimicrob Chemother 45 2000 493 501 (Pubitemid 30199143)
9. W.A. Craig Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1998 1 10 [quiz 11-12]
10. J.M. Rodríiguez-Martínez, C. Pichardo, I. García, M.E. Pachón-Ibañez, F. Docobo-Pérez, and A. Pascual Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1 Clin Microbiol Infect 14 2008 691 697 (Pubitemid 351837030)
11. D.H. McGee, W.F. Holt, P.R. Kastner, and R.L. Rice Safety of moxifloxacin as shown in animal and in vitro studies Surv Ophthalmol 50 Suppl. 1 2005 S46 S54
12. E. von Keutz, and G. Schluter Preclinical safety evaluation of moxifloxacin, a novel fluoroquinolone J Antimicrob Chemother 43 Suppl. B 1999 91 100 (Pubitemid 29231799)
13. M.D. Huband, M.A. Cohen, M. Zurack, D.L. Hanna, L.A. Skerlos, and M.C. Sulavik In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant Gram-positive and fastidious organism groups Antimicrob Agents Chemother 51 2007 1191 1201 (Pubitemid 46586793)
14. Y. Otsu, K. Yanagihara, Y. Fukuda, Y. Miyazaki, K. Tsukamoto, and Y. Hirakata In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model Antimicrob Agents Chemother 47 2003 3699 3703 (Pubitemid 37484974)
15. T. Otani, M. Tanaka, E. Ito, Y. Kurosaka, Y. Murakami, and K. Onodera In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone Antimicrob Agents Chemother 47 2003 3750 3759 (Pubitemid 37484983)